HDBNJ-2812 / Handok, BNJ Biopharma - LARVOL DELTA

Design, synthesis, and evaluation of next-generation EGFR degraders to overcome osimertinib-resistance (AACR 2024) - "The occurrence of C797S mutation in epidermal growth factor receptor (EGFR) is a leading mechanism of clinically acquired resistance to third-generation EGFR inhibitors, including Osimertinib. Additionally, the in vivo PK/PD findings complement this compound's potential to be considered further. HDBNJ2812 may serve as a lead compound to render the greater therapeutic window for treating resistant non-small cell lung cancer patients with EGFR C797S mutants."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR